AI Drug Discovery "Revolution": Can Unconfirmed Breakthroughs Truly Shorten Clinical Trial Timelines?
This article analyzes the claimed breakthrough of AI-driven drug discovery platforms that allegedly shorten the time for new drugs to enter clinical trials, pointing out multiple unresolved uncertainties behind the unconfirmed announcement. It also discusses the technical and commercial reasons for these ambiguities, and calls for evidence-based assessment to distinguish hype from substantive progress in the commercial application of AI in the medical field.